Articles related to "Epidermal Growth Factor Receptors"

There are several well-documented biomarkers and genetic tests on the market today that help oncologists determine the best course of therapy for cancer patients.

Since 2001 the incidence of breast cancer (and its associated mortality) in the U.S. has declined, due in part to therapies guided by receptor status.

Tarceva® (erlotinib) prolongs survival in lung and pancreatic cancers by inhibiting the epidermal growth factor receptor (HER1/EGFR).

Scientist discovered a protein that may aid in the spread of breast cancer. As such, it's a good time to learn about the symptoms and signs of the disease.